Perrigo furthers commitment to Ireland
Dublin headquarters central to European and global growth strategy.
Perrigo Company has announced that a number of key public facing corporate functions will be relocated to Ireland as part of the company's focused international growth strategy and global expansion. This announcement furthers the company's previously announced actions on 22 October 2015 to maximize efficiency and continue leveraging the strength of Perrigo's global platform. A number of positions will also be added to the company's Dublin headquarters across a range of corporate functions including supply chain/global operations, procurement, enterprise risk management and corporate finance and information technology.
Perrigo has long identified Ireland as a gateway for its expansion into Europe. The acquisition of Omega Pharma in 2015, which added a pan-European branded consumer healthcare platform, the transfer of major corporate functions to Ireland, and the expansion of the Company's headquarters underscores Perrigo's commitment to European and international growth.
As part of this expansion, Arthur Shannon will relocate to Ireland and assume the role of Vice President, Global Corporate Affairs and European Investor Relations. In this role Mr Shannon will continue to oversee both internal and external Global Communications and will continue to be the lead point of contact for media. In addition, he will now be responsible for establishing a global government relations base from Dublin and expanding Perrigo's already robust, shareholder focused Investor Relations programs across Europe. Mr Shannon will be moving to Dublin in early April. At that time we will update his contact information.
Separately, Bradley Joseph has been promoted to the role of Vice President, Global Investor Relations. Mr Joseph will lead the investor relations team in designing and executing the relevant strategies, communications and investor outreach programs for the globe. He will continue to be based in Allegan, Michigan.
In addition, Lou Cherico, Vice President, Corporate Treasurer, will relocate to Dublin, to accelerate the buildout of Perrigo's Global Treasury and Risk Management functions in Ireland to better support our international expansion.
Msr. Shannon, Joseph and Cherico will report directly to Judy Brown, Executive Vice President and Chief Financial Officer at Perrigo.
Joe Papa, Chairman and CEO of Perrigo commented: "We are delighted to announce the addition of these key external facing corporate functions to our Dublin base, reinforcing our plans to expand our footprint in Ireland. These additions build on the outstanding Dublin based team currently in place. We are excited about this next chapter in our international growth. The enhancement of our Irish operations furthers the benefits of our global platform and will enable us to drive continued strong profit growth and enhance shareholder value."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance